Citigroup
PRLD icon

Citigroup’s Prelude Therapeutics PRLD Stock Holding History

Citigroup’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.5K Buy
13,033
+13,028
+260,560% +$56.7K ﹤0.01% 4863
2026
Q1 		$17 Buy
5
+4
+400% +$10 ﹤0.01% 5703
2025
Q4 		$3 Sell
1
-5,974
-100% -$10.1K ﹤0.01% 5908
2025
Q3 		$8.6K Buy
5,975
+1,257
+27% +$1.26K ﹤0.01% 5073
2025
Q2 		$3.82K Sell
4,718
-4,582
-49% -$3.97K ﹤0.01% 5310
2025
Q1 		$7.14K Sell
9,300
-915
-9% -$854 ﹤0.01% 5242
2024
Q4 		$13K Buy
10,215
+560
+6% +$743 ﹤0.01% 5338
2024
Q3 		$20K Buy
9,655
+6,641
+220% +$30.8K ﹤0.01% 5189
2024
Q2 		$11.5K Buy
3,014
+205
+7% +$834 ﹤0.01% 5114
2024
Q1 		$13.3K Buy
2,809
+682
+32% +$2.65K ﹤0.01% 5133
2023
Q4 		$9.08K Buy
2,127
+1,601
+304% +$4.87K ﹤0.01% 5216
2023
Q3 		$1.63K Sell
526
-3,315
-86% -$12.4K ﹤0.01% 5016
2023
Q2 		$17.3K Sell
3,841
-66,926
-95% -$400K ﹤0.01% 4990
2023
Q1 		$403K Buy
70,767
+10,695
+18% +$65.2K ﹤0.01% 3272
2022
Q4 		$363K Buy
60,072
+51,540
+604% +$330K ﹤0.01% 3379
2022
Q3 		$56K Buy
8,532
+7,691
+915% +$51.8K ﹤0.01% 4341
2022
Q2 		$4K Sell
841
-878
-51% -$4.47K ﹤0.01% 5704
2022
Q1 		$12K Sell
1,719
-2,359
-58% -$21.6K ﹤0.01% 5439
2021
Q4 		$51K Sell
4,078
-20,190
-83% -$328K ﹤0.01% 5059
2021
Q3 		$758K Sell
24,268
-51,355
-68% -$1.66M ﹤0.01% 3300
2021
Q2 		$2.17M Buy
75,623
+15,026
+25% +$535K ﹤0.01% 2605
2021
Q1 		$2.63M Buy
60,597
+58,866
+3,401% +$3.91M ﹤0.01% 2306
2020
Q4 		$124K Buy
+1,731
New +$86.1K ﹤0.01% 5365

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Citigroup's PRLD Position: Q2 2026 in Review

Citigroup increased its Prelude Therapeutics (PRLD) stake by 260,560% in Q2 2026, buying an estimated $56.7K and bringing the position to 13,033 shares worth $69.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4863.

Citigroup first reported a position in PRLD in Q4 2020 and has held it in 23 quarters since. The position peaked at $2.63M in Q1 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Citigroup held 13,033 shares of Prelude Therapeutics worth $69.5K as of Q2 2026.
  • Citigroup bought 13,028 Prelude Therapeutics shares in Q2 2026, an estimated $56.7K.
  • Prelude Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4863 holding.
  • Citigroup first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Citigroup's Prelude Therapeutics position peaked at $2.63M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.